Compugen
Holon · 1 known investors
Compugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
Founders & leadership
AO
Arie OvadiaNamed on SEC filing
ZL
Zurit LevineNamed on SEC filing
GH
Gilead HalevyNamed on SEC filing
PS
Paul SekhriNamed on SEC filing
HA
Henry AdewoyeNamed on SEC filing
KL
Kinneret Livnat SavitzkyNamed on SEC filing
YA
Yair AharonowitzNamed on SEC filing
JH
John HunterNamed on SEC filing
AC
Anat Cohen-DayagNamed on SEC filing
KA
Kirk A. ChristoffersenNamed on SEC filing
SZ
Sanford ZweifachNamed on SEC filing
JB
Jean-Pierre BizzariNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$32M disclosed across 2 rounds · 2018–2021
▶$20MraisedNov 2021 · 1 investors · BiotechnologyRule 506(b)
▶$20MraisedNov 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Zurit LevineExecutive Officer
- Yaron TurpazExecutive Officer
- Anat Cohen-DayagExecutive Officer, Director
- Sanford ZweifachDirector
- Eran PerryDirector
- Jean-Pierre BizzariDirector
- Kinneret Livnat SavitzkyDirector
- Paul SekhriDirector
- Gilead HalevyDirector
- Oliver FroescheisExecutive Officer
- Henry AdewoyeExecutive Officer
- Ari KrashinExecutive Officer
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Nov 2021
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$12MraisedOct 2018 · 1 investors · OtherRule 506(b)
▶$12MraisedOct 2018 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Arie OvadiaDirector
- Zurit LevineExecutive Officer
- Gilead HalevyDirector
- Paul SekhriDirector
- Henry AdewoyeExecutive Officer
- Kinneret Livnat SavitzkyDirector
- Yair AharonowitzDirector
- John HunterExecutive Officer
- Anat Cohen-DayagExecutive Officer, Director
- Kirk A. ChristoffersenExecutive Officer
- Sanford ZweifachDirector
- Jean-Pierre BizzariDirector
- Ari KrashinExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Oct 2018
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Compugen do?
- Compugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
- Who are Compugen's investors?
- Compugen's investors include Crescendo Venture Partners.
- How much funding has Compugen raised?
- Compugen has disclosed $32M raised across 2 rounds.
- Where is Compugen headquartered?
- Compugen is headquartered in Holon.